InspireMD Eyes Carotid Market Share with FDA Approval on Horizon

InspireMD (NSPR), a developer of carotid artery stenting devices, highlighted its market positioning at the H.C. Wainwright conference on September 14, 2026, as it prepares for FDA approval of its Transcarotid Artery Revascularization (TCAR) indication in early November. The company’s MicroNet stent—a 20-micron mesh outer layer on a self-expanding stent—is designed to reduce the risk of plaque prolapse and post-procedural strokes, with clinical trials showing sub-1% complication rates in carotid stenting procedures. InspireMD’s revenue surged 53% year-over-year to $10.84 million in the trailing twelve months, reflecting a market opportunity valued at $1 billion annually for U.S. carotid interventions, of which TCAR procedures account for roughly 45,000 annually. The company has sold over 75,000 devices across 35 markets over the past decade, with a U.S. sales force of 12 representatives targeting vascular surgeons, interventional cardiologists, and neurosurgeons through a distributor model internationally. InspireMD’s growth has been bolstered by recent financing: a $113 million transformational financing in May 2023, followed by a $40 million private investment in public equity (PIPE) later that year. The company’s valuation remains modest at $36 million, despite its ambitions. In a notable acquisition, Boston Scientific acquired Silk Road Medical for $1.3 billion in 2023, a company that generated about $200 million in annual revenue prior to the deal. InspireMD’s regulatory journey includes CMS approval for standard-risk reimbursement in October 2023 and an FDA recall in May 2026 of its initial delivery system, used about 40 times during the trial, due to friction issues. The company’s clinical pipeline includes the CREST-2 study, a 10-year NIH randomized trial demonstrating that stenting plus medical therapy outperformed medical therapy alone. CEO Marvin Slosman emphasized the company’s competitive edge, likening its position to that of a dominant player in a market dominated by legacy technologies, such as flip phones versus smartphones. He noted that sub-1% complication rates in carotid stenting are unprecedented in the space, positioning InspireMD to capitalize on a market where procedural volumes remain robust, driven by aging populations and rising cardiovascular disease prevalence.